scholarly journals Recurrent renal cell cancer: 10 years or more after nephrectomy

2013 ◽  
Vol 4 (2) ◽  
pp. 45 ◽  
Author(s):  
Emmanuel Abara ◽  
Iolanda Chivulescu ◽  
Nilam Clerk ◽  
Pablo Cano ◽  
Alexis Goth

Localized renal cell carcinoma (RCC) responds well to surgery.Patients often question how long they have to be on surveillanceafter their surgery. Several follow-up patterns have been describedin the literature. Until 2009, no published established Canadianguidelines existed to assist Canadian health-care practitioners inthe surveillance of these patients. We present 3 cases of RCC thatrecurred 10 years or longer after the initial nephrectomy. Thesecases emphasize the need for careful long-term follow-up, as recommendedin the Canadian Urological Association guidelines.We also discuss the optimism of prolonged disease survival inthe era of novel therapeutic agents that target angiogenesis.

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 4597-4597
Author(s):  
V. K. Chand ◽  
J. Sidloski ◽  
G. Clamon ◽  
R. J. Hohl

1994 ◽  
Vol 12 (4) ◽  
pp. 701-706 ◽  
Author(s):  
S Williams ◽  
J A Blessing ◽  
S Y Liao ◽  
H Ball ◽  
P Hanjani

PURPOSE This study was performed to determine the effectiveness of postoperative adjuvant chemotherapy in patients with surgically resected ovarian germ cell tumors. PATIENTS AND METHODS After tumor removal and thorough surgical staging, patients were enrolled on this study and treated with three courses of cisplatin, etoposide, and bleomycin (BEP). Reassessment laparotomy was required of consenting, appropriate patients initially, but became an optional procedure in 1989. RESULTS Of 93 patients assessable on this trial, 89 are continuously free of germ cell cancer. At second-look laparotomy, two other patients were found to have small foci of immature teratoma; both remain clinically free of recurrence. One received subsequent alternate chemotherapy and one did not. Thus, 91 of 93 patients are currently free of germ cell cancer. Follow-up duration ranges from 4.0 to 90.3 months, with 67 patients monitored for longer than 2 years. Acute toxicity was moderate. One patient developed acute myelomonocytic leukemia 22 months after diagnosis. Another patient was noted to have a malignant lymphoma 69 months after protocol treatment. CONCLUSION Three courses of BEP will nearly always prevent recurrence in well-staged patients with completely resected ovarian germ cell tumors and should be given to all such patients. The development of acute leukemia as a complication of treatment is disturbing and mandates careful long-term follow-up, but is unusual and does not alter the risk-to-benefit ratio of treatment.


2018 ◽  
Vol 143 (5) ◽  
pp. 643-647 ◽  
Author(s):  
Tsung-Heng Tsai ◽  
Wen-Ying Lee

Succinate dehydrogenase (SDH)–deficient renal cell carcinoma is a recently recognized distinct subtype of renal cell carcinoma in the 2016 World Health Organization classification. It is associated with SDH gene germline mutations, which also cause paraganglioma/pheochromocytoma, gastrointestinal stromal tumor, and pituitary adenoma. The tumor most commonly presents in young adulthood. The tumors are arranged in solid nests or in tubules and frequently show cystic change. The tumors are composed of cuboidal to oval cells with round nuclei, dispersed chromatin, and inconspicuous nucleoli. The cytoplasm is eosinophilic or flocculent but not truly oncocytic. The most distinctive histologic feature is the presence of cytoplasmic vacuoles or inclusions. Loss of SDH subunit B immunostaining is needed for a definite diagnosis. The prognosis is good for low-grade tumors but worse for tumors with high-grade nuclei, sarcomatoid change, or coagulative necrosis. Long-term follow-up is indicated.


Sign in / Sign up

Export Citation Format

Share Document